Methylation of α-synuclein and leucine-rich repeat kinase 2 in leukocyte DNA of Parkinson's disease patients

Parkinsonism and Related Disorders

Volumn 20, Issue 3, 2014, Pages 308-313

  Tan, Yu yan ^a   Wu, Li ^a   Zhao, Zong bo ^a   Wang, Ying ^a   Xiao, Qin ^a   Liu, Jun ^a   Wang, Gang ^a   Ma, Jian fang ^a   Chen, Sheng di ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

DNA methylation; LRRK2; Parkinson's disease; SNCA

Indexed keywords

ALPHA SYNUCLEIN; DNA; LEUCINE RICH REPEAT KINASE 2; MESSENGER RNA; BIOLOGICAL MARKER; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CPG ISLAND; DISEASE DURATION; DISEASE SEVERITY; DNA EXTRACTION; DNA METHYLATION; DNA MODIFICATION; FEMALE; GENDER; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC MARKER; HUMAN; LEUKOCYTE; LRRK2 GENE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SNCA GENE; AGED; BRAIN; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; BIOLOGICAL MARKERS; BRAIN; CPG ISLANDS; DNA; DNA METHYLATION; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84896395490     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2013.12.002     Document Type: Article

References (32)

1. Qureshi I.A., Mehler M.F. Advances in epigenetics and epigenomics for neurodegenerative diseases. Curr Neurol Neurosci Rep 2011, 11:464-473.
2. Marques S.C., Oliveira C.R., Pereira C.M., Outeiro T.F. Epigenetics in neurodegeneration: a new layer of complexity. Prog Neuropsychopharmacol Biol Psychiatry 2011, 30(35):348-355.
3. Migliore L., Coppedè F. Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases. Mutat Res 2009, 667:82-97.
4. Jiricny J., Menigatti M. DNA cytosine demethylation: are we getting close?. Cell 2008, 135:1167-1169.
5. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
6. Chartier-Harlin M.C., Kachergus J., Roumier C., Mouroux V., Douay X., Lincoln S., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
7. Maraganore D.M., de Andrade M., Elbaz A., Farrer M.J., Ioannidis J.P., Krüger R., et al. Collaborative analysis of α-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296:661-670.
8. Pankratz N., Wilk J.B., Latourelle J.C., DeStefano A.L., Halter C., Pugh E.W., et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 2009, 124:593-605.
9. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010, 74:97-109.
10. Huang Y., Chegini F., Chua G., Murphy K., Gai W., Halliday G.M. Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation. Transl Neurodegener 2012, 1:2.
11. Jowaed A., Schmitt I., Kaut O., Wullner U. Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. JNeurosci 2010, 30:6355-6359.
12. Matsumoto L., Takuma H., Tamaoka A., Kurisaki H., Date H., Tsuji S., et al. CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease. PLoS One 2010, 5:e15522.
13. Satake W., Nakabayashi Y., Mizuta I., Hirota Y., Ito C., Kubo M., et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet 2009, 41:1303-1307.
14. Simon-Sanchez J., Schulte C., Bras J.M., Sharma M., Gibbs J.R., Berg D., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet 2009, 41:1308-1312.
15. Cho H.J., Liu G., Jin S.M., Parisiadou L., Xie C., Yu J., et al. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet 2013, 22:608-620.
16. Lin X., Parisiadou L., Gu X.L., Wang L., Shim H., Sun L., et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's disease-related mutant alpha-synuclein. Neuron 2009, 64:807-827.
17. Gui Y.X., Wan Y., Xiao Q., Wang Y., Wang G., Chen S.D. Verification of expressions of Kir2 as potential peripheral biomarkers in lymphocytes from patients with Parkinson's disease. Neurosci Lett 2011, 505(2):104-108.
18. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010, 74:97-109.
19. Farrer M.J., Stone J.T., Lin C.H., Dächsel J.C., Hulihan M.M., Haugarvoll K., et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 2007, 13:89-92.
20. de Boni L., Tierling S., Roeber S., Walter J., Giese A., Kretzschmar H.A. Next-generation sequencing reveals regional differences of the α-synuclein methylation state independent of Lewy body disease. Neuromolecular Med 2011, 13:310-320.
21. Ladd-Acosta C., Pevsner J., Sabunciyan S., Yolken R.H., Webster M.J., Dinkins T., et al. DNA methylation signatures within the human brain. Am J Hum Genet 2007, 81:1304-1315.
22. Richter J., Appenzeller S., Ammerpohl O., Deuschl G., Paschen S., Brüggemann N., et al. No evidence for differential methylation of α-synuclein in leukocyte DNA of Parkinson's disease patients. Mov Disord 2012, 27:590-591.
23. Clark S.J., Statham A., Stirzaker C., Molloy P.L., Frommer M. DNA methylation: bisulphite modification and analysis. Nat Protoc 2006, 1(5):2353-2364.
24. Feany M.B., Bender W.W. ADrosophila model of Parkinson's disease. Nature 2000, 404:394-398.
25. Maries E., Dass B., Collier T.J., Kordower J.H., Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003, 4:727-738.
26. Miller D.W., Hague S.M., Clarimon J., Baptista M., Gwinn-Hardy K., Cookson M.R., et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 2004, 62:1835-1838.
27. Farrer M., Kachergus J., Forno L., Lincoln S., Wang D.S., Hulihan M., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol 2004, 55:174-179.
28. Desplats P., Spencer B., Coffee E., Patel P., Michael S., Patrick C., et al. Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases. JBiol Chem 2011, 286(11):9031-9037.
29. Li L., Choi J.Y., Lee K.M., Sung H., Park S.K., Oze I., et al. DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. JEpidemiol 2012, 22:384-394.
30. Gormally E., Hainaut P., Caboux E., Airoldi L., Autrup H., Malaveille C., et al. Amount of DNA in plasma and cancer risk: a prospective study. Int J Cancer 2004, 111:746-749.
31. Sharma P., Sahni N.S., Tibshirani R., Skaane P., Uradal P., Berghagen H., et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 2005, 7:R634-R644.
32. Wu H.C., Delgado-Cruzata L., Flom J.D., Kappil M., Ferris J.S., Liao Y., et al. Global methylation profiles in DNA from different blood cell types. Epigenetics 2011, 6:76-85.